Renalytix PLC (RNLX) - מקדם חוב לטווח ארוך להון

Renalytix Plc (RNLX) revenue relies on the implementation of KidneyIntelX AI diagnostics for clinics and patients with diabetes, where insurers cover the costs. The price action (separate_debt_long_eq) recorded a metric of 0.00. While experts recognize the brand for its blood analysis accuracy in renal pathologies, management is currently fighting an urgent battle for asset liquidity, attempting to restore undermined shareholder confidence by seeking new strategies.

Renalytix Plc (RNLX) is developing AI diagnostics, where profit growth rates are constrained by complex tariff negotiations with insurance companies. The capital requirements for scaling KidneyIntelX directly impact the borrowing structure relative to owner assets. This indicator assesses the share of loans with a maturity exceeding one year within the total capital. An analysis of the ratio between long-term debt and equity reveals the company's resilience to Fed policy. This chart's dynamics determine the risk of excessive leverage.